Provided by Tiger Trade Technology Pte. Ltd.

Rocket Pharmaceuticals, Inc.

3.78
+0.25007.08%
Post-market: 3.72-0.0600-1.59%19:46 EDT
Volume:2.20M
Turnover:8.24M
Market Cap:414.95M
PE:-22.24
High:3.81
Open:3.54
Low:3.54
Close:3.53
52wk High:5.45
52wk Low:2.53
Shares:109.77M
Float Shares:84.96M
Volume Ratio:2.00
T/O Rate:2.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1700
EPS(LYR):-2.0100
ROE:-4.77%
ROA:-28.42%
PB:1.13
PE(LYR):-1.88

Loading ...

Don't Ignore The Insider Selling In Rocket Pharmaceuticals

Simply Wall St.
·
Aug 15

MacroGenics Q2 Revenue Misses Estimates, Posts Profit on Asset Sale

Reuters
·
Aug 14

MeiraGTx Q2 Revenue Jumps on Reogen License Revenue

Reuters
·
Aug 13

Rocket Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Abeona Therapeutics Q2 Net Loss Widens, Misses Analyst Expectations

Reuters
·
Aug 13

Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says

MT Newswires Live
·
Aug 12

Rocket Pharmaceuticals Price Target Cut to $15.00/Share from $16.00 by Wedbush

Dow Jones
·
Aug 11

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Sonida Senior Living (SNDA) and TELA Bio (TELA)

TIPRANKS
·
Aug 11

Wedbush Adjusts PT on Rocket Pharmaceuticals to $15 From $16, Keeps Outperform Rating

MT Newswires Live
·
Aug 11

Cantor Fitzgerald Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Aug 11

Rocket Pharmaceuticals, Inc. Expected to Post a Loss of 42 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Aug 11

Rocket Pharmaceuticals, Inc. : Leerink Partners Cuts Target Price to $7 from $12

THOMSON REUTERS
·
Aug 11

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Aug 11

Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate

Benzinga Earnings
·
Aug 11

Rocket Pharmaceuticals Posts Q2 Profit Helped by PRV Sale

Reuters
·
Aug 11

Rocket Pharma Swings to Q2 FY26 Net Income of $123.2 Million; R&D Expenses Fall 30.92% to $29.5 Million

Reuters
·
Aug 11

Rocket Pharmaceuticals Q2 EPS USD 1.08

Reuters
·
Aug 11

Rocket Pharmaceuticals, Inc.: Cash, Cash Equivalents and Investments of About $283.7 Mln; Expected Cash Runway into Q2 of 2028

THOMSON REUTERS
·
Aug 11

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

THOMSON REUTERS
·
Aug 11